A 35-year-old woman from Delhi is diagnosed with HIV infection during antenatal screening at 20 weeks of gestation. Her CD4 count is 350 cells/μL and viral load is 45,000 copies/mL. She is counseled about vertical transmission risk and wishes to continue the pregnancy. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context Pregnant woman with newly diagnosed HIV at CD4 350 cells/μL. The goal is to reduce mother-to-child transmission (MTCT) risk to < 2% through maternal viral suppression and appropriate delivery management. ## Prevention of Mother-to-Child Transmission (PMTCT) Algorithm ```mermaid flowchart TD A[HIV+ pregnant woman]:::outcome --> B{CD4 count?}:::decision B -->|< 200| C[Start ART immediately<br/>regardless of trimester]:::action B -->|200-350| D[Start ART immediately<br/>for PMTCT]:::action B -->|> 350| E{Viral load?}:::decision E -->|> 1000| F[Start ART immediately]:::action E -->|< 1000| G[Consider ART for maternal<br/>health + PMTCT]:::action C --> H[Preferred regimen:<br/>2 NRTIs + PI/r or INSTI]:::action D --> H F --> H G --> H H --> I[Vaginal delivery if<br/>VL < 1000 copies/mL]:::action H --> J[Cesarean if VL > 1000<br/>or unknown]:::action I --> K[Infant prophylaxis:<br/>AZT + 3TC + NVP]:::outcome J --> K ``` ## Key Point: **All HIV+ pregnant women should receive ART regardless of CD4 count or viral load.** This patient's CD4 of 350 and VL of 45,000 are clear indications for immediate ART initiation. ## High-Yield: - **Timing:** ART should be started immediately at any gestational age; there is NO safe window to defer. - **First-line regimen in pregnancy:** Efavirenz-based (if CD4 > 200) OR Integrase inhibitor (dolutegravir) + 2 NRTIs. Avoid protease inhibitors in first trimester if possible (teratogenicity data limited). - **Delivery route:** Vaginal delivery is safe if maternal viral load < 1000 copies/mL on ART. Cesarean section if VL > 1000 or unknown. - **Infant prophylaxis:** All infants born to HIV+ mothers receive AZT + 3TC + nevirapine (or other regimens per NACO guidelines). - **Breastfeeding:** NOT recommended in India (formula feeding is standard). ## Clinical Pearl: **Maternal viral suppression to < 1000 copies/mL by delivery reduces MTCT risk to < 2%.** This is the primary goal of PMTCT. ## Warning: ~~Deferring ART until third trimester~~ increases MTCT risk and is contraindicated. Organogenesis concerns are outweighed by the benefit of maternal viral suppression. ~~Amniocentesis for fetal HIV status~~ is not standard practice and delays maternal treatment. Fetal status is determined postnatally via infant testing. [cite:Park 26e Ch 8, NACO Guidelines on PMTCT]